[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ES2158146T3 - Agente para influir sobre trastornos de la formacion osea. - Google Patents

Agente para influir sobre trastornos de la formacion osea.

Info

Publication number
ES2158146T3
ES2158146T3 ES95943170T ES95943170T ES2158146T3 ES 2158146 T3 ES2158146 T3 ES 2158146T3 ES 95943170 T ES95943170 T ES 95943170T ES 95943170 T ES95943170 T ES 95943170T ES 2158146 T3 ES2158146 T3 ES 2158146T3
Authority
ES
Spain
Prior art keywords
osea
disorders
alkaline
lactates
influate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95943170T
Other languages
English (en)
Inventor
Hans Dietl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orthomol Pharmazeutische Vertriebsgesellschaft mbH
Original Assignee
Orthomol Pharmazeutische Vertriebsgesellschaft mbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orthomol Pharmazeutische Vertriebsgesellschaft mbH filed Critical Orthomol Pharmazeutische Vertriebsgesellschaft mbH
Application granted granted Critical
Publication of ES2158146T3 publication Critical patent/ES2158146T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA INVENCION TRATA DE UN MEDIO PARA LA PROFILAXIS Y/O TERAPIA DE ESTADOS QUE VIENEN ACOMPAÑADOS DE TRASTORNOS DE OSIFICACION. DICHO MEDIO CONTIENE CITRATOS ALCALINOS Y/O LACTATOS ALCALINOS Y/O MALATOS ALCALINOS, OPCIONALMENTE, JUNTO CON UNA O VARIAS SUSTANCIAS ACTIVAS SELECCIONADAS DE LA VITAMINA K, SALES DE CALCIO Y VITAMINA D. EL MEDIO CONTIENE PREFERENTEMENTE CITRATOS DE POTASIO Y/O CITRATOS SODICOS O LACTATOS DE POTASIO Y/O LACTATOS SODICOS Y SIRVE PARA LA PROFILAXIS Y/O TERAPIA DE LA DESMINERALIZACION OSEA, EN PARTICULAR, DE LA OSTEOPOROSIS O OSTEOMALACIA.
ES95943170T 1995-02-01 1995-12-20 Agente para influir sobre trastornos de la formacion osea. Expired - Lifetime ES2158146T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19503190A DE19503190A1 (de) 1995-02-01 1995-02-01 Mittel zur Beeinflussung von Störungen der Knochenbildung

Publications (1)

Publication Number Publication Date
ES2158146T3 true ES2158146T3 (es) 2001-09-01

Family

ID=7752867

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95943170T Expired - Lifetime ES2158146T3 (es) 1995-02-01 1995-12-20 Agente para influir sobre trastornos de la formacion osea.

Country Status (8)

Country Link
US (1) US5985335A (es)
EP (1) EP0806953B1 (es)
JP (1) JP3712732B2 (es)
BR (1) BR9510162A (es)
CA (1) CA2211177C (es)
DE (2) DE19503190A1 (es)
ES (1) ES2158146T3 (es)
WO (1) WO1996023504A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19503190A1 (de) * 1995-02-01 1996-08-08 Dietl Hans Mittel zur Beeinflussung von Störungen der Knochenbildung
GB9713620D0 (en) * 1997-06-28 1997-09-03 Boots Co Plc Composition
JP4592127B2 (ja) * 1999-03-30 2010-12-01 雪印乳業株式会社 骨吸収抑制剤
GB2370503A (en) * 2000-12-27 2002-07-03 Novartis Nutrition Ag Compositions comprising vitamin K
CA2440261C (en) * 2001-03-15 2014-05-27 Roche Vitamins Ag Composition for the prevention of osteoporosis comprising a combination of isoflavones and polyunsaturated fatty acids
DE10135494A1 (de) * 2001-07-20 2003-11-06 Jobst Krauskopf Verwendung eines Lactatsalzes zur Behandlung und Prophylaxe der Athereosklerose
US20070077314A1 (en) * 2005-07-15 2007-04-05 Pak Charles Y C Powder mix of potassium calcium citrate for the treatment of kidney stones and osteoporosis
US20110092426A1 (en) * 2007-08-09 2011-04-21 Novartis Ag Oral calcitonin compositions and applications thereof
DE202009018772U1 (de) * 2008-06-03 2013-03-15 John Ray Biffin Zusammensetzung enthaltend Vitamin K und ihre Verwendung

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2530372A1 (de) * 1975-07-08 1977-01-13 Walter Dr Schweckendiek Pharmazeutische zubereitungen zur behandlung von psoriasis
JPS5218811A (en) * 1975-08-01 1977-02-12 Eisai Co Ltd Preparation of aqueous solution of fat- soluble substances
JPS61267528A (ja) * 1984-11-26 1986-11-27 Yamanouchi Pharmaceut Co Ltd 吸収促進剤を含有するカルシトニン経鼻剤
FR2600893B1 (fr) * 1986-07-01 1990-01-12 Sandoz Lab Nouvelles compositions pharmaceutiques a base de sels de calcium
IL89392A (en) * 1988-03-23 1993-02-21 Teva Pharmaceutical Ind Ltd Je Compositions for the treatment of osteoporosis in humans comprising 24, 25-dihydroxy-vitamin d3
US5182274A (en) * 1988-09-26 1993-01-26 Teijin Limited Stabilized aqueous preparation of active form of vitamin d3
DE4111040C1 (es) * 1991-04-05 1992-06-17 Deutsche Granini Gmbh & Co Kg, 4800 Bielefeld, De
CZ236793A3 (en) * 1991-05-06 1994-04-13 Procter & Gamble Combined complement containing calcium and vitamin d
SK132693A3 (en) * 1991-05-28 1994-06-08 Procter & Gamble Calcium, trace mineral, vitamin d and drug therapy combinations
JPH05213763A (ja) * 1992-02-10 1993-08-24 Sanwa Kagaku Kenkyusho Co Ltd 易吸収活性化カルシウム製剤
FR2704393B1 (fr) * 1993-04-30 1995-06-02 Boiron Complément nutritionnel absorbable pour optimiser la croissance et maintenir la solidité des os.
US5389391A (en) * 1993-05-10 1995-02-14 Monte; Woodrow C. Low pH antimicrobial food composition
US5780451A (en) * 1994-04-01 1998-07-14 Abbott Laboratories Nutritional product for a person having ulcerative colitis
EP0704199B1 (en) * 1994-04-20 2003-03-19 Mitsubishi Pharma Corporation Transfusion container, transfusion preparation, and comprehensive vitamin-containing high-calorie transfusion preparation
DE19503190A1 (de) * 1995-02-01 1996-08-08 Dietl Hans Mittel zur Beeinflussung von Störungen der Knochenbildung

Also Published As

Publication number Publication date
CA2211177A1 (en) 1997-10-15
JP3712732B2 (ja) 2005-11-02
JPH10513162A (ja) 1998-12-15
DE59509370D1 (de) 2001-08-02
WO1996023504A2 (de) 1996-08-08
US5985335A (en) 1999-11-16
EP0806953B1 (de) 2001-06-27
CA2211177C (en) 2005-05-24
EP0806953A2 (de) 1997-11-19
WO1996023504A3 (de) 1996-09-26
DE19503190A1 (de) 1996-08-08
BR9510162A (pt) 1998-11-10

Similar Documents

Publication Publication Date Title
AR005861A1 (es) Una composicion liquida de limpieza de la piel ,y un metodo para potenciar el efecto antimicrobiano de formulaciones de limpieza de la piel
ES2099644T3 (es) Composicion cosmetica y/o dermatologica que contiene agua termal o mineral y un agente activo para luchar contra el acne o el envejecimiento.
ES2154388T3 (es) Utilizacion de un antagonista de cgrp en una composicion cosmetica, farmaceutica o dermatologica y composicion obtenida.
MX9201733A (es) Limpiador para la piel de agente tensioactivo liquido, suave, antibacteriano.
BR9612661A (pt) Utilização de uma combinaç i de tensoatives agentes quelantes e óleos essenciais para desinfecção eficaz
ES2073205T3 (es) Agentes con efecto refrigerante fisiologico y compuestos activos apropiados para estos agentes.
ES2158146T3 (es) Agente para influir sobre trastornos de la formacion osea.
ES2176700T3 (es) Composiciones para la piel.
AR020010A1 (es) Toallita prehumedecida y regimen para el cuidado de la piel
CO5150154A1 (es) Composicion de sustrato y metodo para usarlo para el secuestro de irritantes de la piel
ES2094669T3 (es) Composiciones a base de un sistema abrasivo y de un sistema tensioactivo.
PA8484301A1 (es) Formulaciones farmaceuticas de liberacion controlada
BR9813677A (pt) Composição para cuidado oral, e, uso de um ácido poliacrìlico totalmente neutralizado
ES2162029T3 (es) Composiciones para el cuidado personal y productos de paños de frotar que contienen a las composiciones.
BR0013157A (pt) Composições farmacêuticas e nutricionais contendo ácidos graxos essenciais e agentes de abaixamento da homocisteìna
PA8454401A1 (es) SALES DE SERTRALINA Y FORMAS DE DOSIFICACiON DE LIBERACION SOSTENIDA DE SERTRALINA
NO180089C (no) Antimikrobiell formulering for påföring på hud
FI931717A (fi) Vattenhaltigt gel som doseringsform foer retinoid
NO20004721L (no) Bruseformuleringer
AR022420A1 (es) Composiciones en barra que contienen tensioactivos anfoteros solidos
ES2037866T3 (es) Una composicion desodorante en forma de gel.
BR9815747A (pt) Composição para liberação de aroma
ES2118009T3 (es) Utilizacion de un antagonista de bradiquinina en una composicion cosmetica, farmaceutica o dermatologica y composicion obtenida.
NO983608D0 (no) Anti-stein munnpleiemiddel inneholdende höy-löselig pyrofosfat
AR010716A1 (es) Formulacion para tabletas efervecentes desinfectantes y metodo para formar una solucion desinfectante

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 806953

Country of ref document: ES